Phase II Clinical Study of AC591 in Preventing Oxaliplatin-Induced Peripheral Neuropathy

NCT06722950 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Adenoma

Interventions

DRUG: CAPEOX
DRUG: Placebo
DRUG: AC591

Sponsor

Shandong New Time Pharmaceutical Co., LTD